Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1983-6-10
pubmed:abstractText
The pharmacokinetics of cefoperazone, cefotaxime, and moxalactam were compared in a cross-over randomized study in 10 healthy volunteers. Each subject received 1.0 g of the three drugs by bolus intravenous injection over 3 min. Serum and urine concentrations were assayed by a microbiological method and in addition by high-pressure liquid chromatography (HPLC) for cefotaxime in five subjects. Maximal concentrations in serum 5 min after the injection were 163 +/- 40.3 mg/liter for cefoperazone, 86.1 +/- 19.0 mg/liter for cefotaxime, and 95.5 +/- 21.1 mg/liter for moxalactam. After 12 h, 1.2 +/- 1.4 mg of cefoperazone per liter and 1.8 +/- 0.9 mg of moxalactam per liter could still be measured. Eight hours after the administration of cefotaxime, serum concentrations were below the detection limit of 0.3 mg/liter in most subjects. By HPLC analysis, the mean maximal concentration of desacetyl cefotaxime was 16.6 +/- 10.5 mg/liter 5 min after application; the metabolite exceeded the serum concentration of the parent compound after 1 to 2 h. Relevant pharmacokinetic parameters were calculated, using two- and three-compartment models. The terminal half-life was 144.1 +/- 37.3 min for cefoperazone, 76.1 +/- 32.0 min for cefotaxime, and 272.4 +/- 114.1 min for moxalactam. The apparent volume of distribution corresponded to the extracellular volume. Only 25.1 +/- 8% of cefoperazone could be detected in urine compared with 53.3 +/- 8.1% of cefotaxime and 61.0 +/- 9.2% of moxalactam in 24 h. A total of 89.6 +/- 11.4% of the cefotaxime dose could be recovered by HPLC in urine, 60.6 +/- 7.7% as cefotaxime and 29.1 +/- 7.0% as desacetyl cefotaxime.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-1101062, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-314775, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-426518, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-485125, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-526000, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-5411325, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-6214988, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-6214989, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-6248221, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-6252138, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-6252184, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-6252185, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-6252831, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-6252833, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-6264849, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-6275776, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-6446259, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-6446395, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-6446398, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-6446399, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-6446400, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-6453555, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-6453556, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-6454383, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-6454387, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-6454389, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-6455966, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-6455967, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-6457558, http://linkedlifedata.com/resource/pubmed/commentcorrection/6303213-7249588
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
429-34
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1983
pubmed:articleTitle
Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial